Cargando…

Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial

STUDY QUESTION: Is corifollitropin alfa 150 μg equivalent to follitropin beta 300 IU/day for controlled ovarian hyperstimulation (COS) in older women weighing ≥50 kg undergoing IVF and/or ICSI in Vietnam? SUMMARY ANSWER: Corifollitropin alfa 150 μg was equivalent to follitropin beta 300 IU/day with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vuong, N L, Pham, D T, Phung, H T, Giang, H N, Huynh, G B, Nguyen, T T L, Ho, M T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276648/ https://www.ncbi.nlm.nih.gov/pubmed/30895237 http://dx.doi.org/10.1093/hropen/hox023

Ejemplares similares

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis
por: Fensore, Stefania, et al.
Publicado: (2015)

Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
por: Leader, Arthur, et al.
Publicado: (2013)

Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol
por: Griesinger, Georg, et al.
Publicado: (2016)

Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction
por: Souza, Priscila Morais Galvão, et al.
Publicado: (2017)

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art
por: Carvalho, Bruno Ramalho de
Publicado: (2023)

Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study
por: Barrenetxea, Gorka, et al.
Publicado: (2018)

The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist
por: Seyhan, Ayse, et al.
Publicado: (2011)

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
por: Devroey, P., et al.
Publicado: (2009)

Corifollitropin alfa for poor responders patients, a prospective randomized study
por: Fusi, F. M., et al.
Publicado: (2020)

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
por: Khoa, Le Dang, et al.
Publicado: (2020)

Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients
por: Selman, Helmy, et al.
Publicado: (2016)

A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders
por: Wang, Huai-Ling, et al.
Publicado: (2016)

Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing in vitro fertilization cycles
por: Akarsu, Süleyman, et al.
Publicado: (2017)

Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles
por: Oehninger, Sergio, et al.
Publicado: (2015)

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity
por: Norman, Robert J., et al.
Publicado: (2011)

Corifollitropin- [Formula: see text] compared to daily r-FSH in for patients undergoing intracytoplasmic sperm injection: Clinical trial study
por: Zahiri Sorouri, Ziba, et al.
Publicado: (2019)

Association of progesterone production with serum anti-Müllerian hormone levels in assisted reproductive technology cycles with corifollitropin alfa
por: Lee, Tsung-Hsien, et al.
Publicado: (2018)

Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol
por: Salgueiro, Lister L., et al.
Publicado: (2016)

Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction
por: Park, Hyo Young, et al.
Publicado: (2015)

An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism
por: Nieschlag, Eberhard, et al.
Publicado: (2017)

Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study
por: Tsakiridis, Ioannis, et al.
Publicado: (2020)

Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial
por: Alvarado Franco, Carlos Alberto, et al.
Publicado: (2023)

A new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot study
por: Decleer, W., et al.
Publicado: (2014)

Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders
por: Errázuriz, Joaquín, et al.
Publicado: (2019)

Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol
por: Huang, Ting-Chi, et al.
Publicado: (2021)

FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation
por: Abbara, Ali, et al.
Publicado: (2019)

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
por: D’Amato, Giuseppe, et al.
Publicado: (2023)

Laparoscopic Myomectomy of a 4.2 kg Fibroid with Assistance of a Minilaparotomy
por: Conrad, Dean Helmar, et al.
Publicado: (2018)

Chlorine. (CL.—35.42.)
por: Watt, G.
Publicado: (1855)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Effects of Extra-Long-Acting Recombinant Bovine FSH (bscrFSH) on Cattle Superovulation
por: Gutiérrez-Reinoso, Miguel A., et al.
Publicado: (2022)

ALFA Detector Control System
por: Oleiro Seabra, Luis Filipe
Publicado: (2015)

ALFA Detector Control System
por: Oleiro Seabra, Luis Filipe
Publicado: (2015)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35–50 kg/m(2)
por: Patel, Prashant, et al.
Publicado: (2023)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2
por: Xu, Xueqing, et al.
Publicado: (2009)

Comparison between cycles of the same patients when using recombinant luteinizing hormone + recombinant follicle stimulating hormone (rFSH), human menopausal gonadotropin + rFSH and rFSH only
por: Tayyar, Ahter Tanay, et al.
Publicado: (2018)

Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?
por: Bentov, Yaakov, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6si18ql5uj4tivpsqeqkgmd488